Inaktiver Wert

Andere Sprachen Fresh Start Private Management Inc Other OTC

Aktien

US35804J1025

Schlusskurs Other OTC Andere Börsenplätze
- ^USD	-

15.05.	BioCorRx Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
03.04.	BioCorRx Inc. kündigt Rücktritt des Vorstands an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioCorRx Reports Business Update for the First Quarter of 2024	16.05.
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
BioCorRx Inc. Announces Board Resignations	03.04.
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	03.04.
BioCorRx Reports Business Update for 2023	02.04.
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	28.02.
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	08.02.
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	08.02.
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	09.01.
BioCorRx Inc. Announces President Changes	05.01.
BioCorRx : Material Agreement - Form 8-K	15.12.
BioCorRx Inc. announced that it has received $0.2 million in funding	08.12.
BioCorRx Reports Business Update for the Third Quarter of 2023	14.11.
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
BioCorRx Inc. announced that it has received $0.2 million in funding	10.11.
Biocorrx Inc. Announces Management Changes	02.11.
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15.08.23
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15.08.23
BioCorRx Reports Business Update for the Second Quarter of 2023	14.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Fresh Start Private Management Inc Other OTC

Aktien

US35804J1025

Andere Sprachen

Filter